Waltham, United States
Third Pole Therapeutics, founded in 2014 and headquartered in the United States, is at the forefront of developing next-generation cardiopulmonary therapies under the slogan "Transformative Cardiopulmonary Therapy." The company is revolutionizing the medical device industry by building on its expertise in inhaled nitric oxide (NO) therapies—the current standard of care.
Their first innovation is a compact, economical, and lightweight device capable of generating NO from air on-site and on-demand. This approach potentially eliminates reliance on large compressed gas cylinders, facilitating broader, worldwide use in non-acute care settings, promising to tap into new markets.
With a recent $32.00M Series B investment secured on 14 December 2022, Third Pole Therapeutics aims to accelerate its growth trajectory and enhance its product offerings. The firm's potential to disrupt traditional methods, coupled with its strategic innovation, positions it as a promising opportunity for investors within the Hospitality and Medical Devices sectors.
